ChroMedX Retains DxEconomix for Commercialization Strategy
August 21, 2017 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has retained Glendale, California based IVD marketing specialists DxEconomix Inc.
DxEconomix led by Dr. Richard Janeczko will work with ChroMedX to evaluate/analyze the patented HemoPalm Blood Analyzer System’s value offering, forecasting, commercialization and marketing plan in preparation for commercial launch of the technology in 2018.
“We are excited to identify new applications and further explore the economic value of the HemoPalm. The expertise of Dr. Janeczko and DxEconomix is a perfect addition to ChroMedX’s strategic initiatives and we look forward to their analysis and formalization of the HemoPalms introduction to market.” said Ash Kaushal, President & CEO, ChroMedX Corp.
DxEconomix provides unique IVD marketing services based on healthcare system-wide economic impact analyses for new products and services. Dr. Janeczko is a 25 year veteran of the in-vitro diagnostic industry and has played executive and advisory roles specializing in the marketing and management of molecular and sequencing assays, proteomics, companion diagnostics, and personalized medicine.
“Success in today’s healthcare reform environment is driven by both clinical and economic impacts of new products and services. Health economic analyses establishes real world value propositions and forms the basis for value-based pricing strategies and maximizing ROI’s. At Dx Economix we are very excited to be working with ChroMedX and the HemoPalm product line.” said Dr. Richard Janeczko CEO, DxEconomix Inc.
DxEconomix’s initial focus will be to thoroughly explore the value of the HemoPalm’s combined POCT analysis. The collaboration will establish a path to market related to health economics, clinical sciences, and health technology assessment and adoption in multiple markets including USA, Canada and Europe. Dr. Janeczko and DxEconomix will play an integral role on multiple fronts as the Company’s technology advances towards commercialization.
About DxEconomix, Inc.
DxEconomix Inc. is a marketing group providing assistance to medical device companies including IVD businesses. Using health economic impact analyses we define the positioning landscape, value proposition and value-based pricing options for client services and products. In this way we help our clients understand the real value they bring to healthcare systems, how to use this to obtain better pricing and better understand returns on their investments. We also work with clients to optimize design inputs for new tests or adapt existing diagnostics. We develop modes of application and source key technologies to create products to overcomes market access obstacles. DxEx helps broker commercial relationships between clients and key stakeholders providing new market channels to IVD companies and creating value for healthcare systems.
The Company also announces the grant of 200,000 options a price of $0.25 CAD